Livforsakringsbolaget Skandia’s BioMarin Pharmaceuticals BMRN Stock Holding History

Livforsakringsbolaget Skandia’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,720	Closed	-$93.1K	–	488
2025 Q3	$93.1K	Hold	1,720	–	–	﹤0.01%	474
2025 Q2	$94.5K	Hold	1,720	–	–	﹤0.01%	486
2025 Q1	$121K	Hold	1,720	–	–	0.01%	478
2024 Q4	$113K	Hold	1,720	–	–	0.01%	487
2024 Q3	$121K	Buy	1,720 +1,400	+438%	+$117K	0.01%	495
2024 Q2	$26.3K	Hold	320	–	–	﹤0.01%	461
2024 Q1	$27.9K	Hold	320	–	–	﹤0.01%	470
2023 Q4	$30.9K	Hold	320	–	–	﹤0.01%	448
2023 Q3	$28.3K	Hold	320	–	–	﹤0.01%	421
2023 Q2	$27.7K	Hold	320	–	–	﹤0.01%	432
2023 Q1	$31.1K	Hold	320	–	–	﹤0.01%	423
2022 Q4	$33.1K	Hold	320	–	–	﹤0.01%	394
2022 Q3	$27K	Sell	320 -1,100	-77%	-$97.9K	﹤0.01%	415
2022 Q2	$118K	Sell	1,420 -2,200	-61%	-$175K	0.01%	433
2022 Q1	$279K	Hold	3,620	–	–	0.02%	389
2021 Q4	$320K	Hold	3,620	–	–	0.02%	383
2021 Q3	$280K	Hold	3,620	–	–	0.02%	449
2021 Q2	$302K	Buy	3,620 +1,800	+99%	+$143K	0.02%	475
2021 Q1	$137K	Hold	1,820	–	–	0.01%	533
2020 Q4	$160K	Hold	1,820	–	–	0.01%	485
2020 Q3	$138K	Hold	1,820	–	–	0.01%	468
2020 Q2	$224K	Hold	1,820	–	–	0.03%	363
2020 Q1	$154K	Hold	1,820	–	–	0.02%	389
2019 Q4	$154K	Sell	1,820 -500	-22%	-$37.8K	0.02%	405
2019 Q3	$156K	Hold	2,320	–	–	0.02%	454
2019 Q2	$199K	Buy	2,320 +700	+43%	+$59.9K	0.02%	403
2019 Q1	$144K	Hold	1,620	–	–	0.02%	409
2018 Q4	$138K	Hold	1,620	–	–	0.02%	384
2018 Q3	$157K	Sell	1,620 -1,900	-54%	-$190K	0.02%	430
2018 Q2	$332K	Hold	3,520	–	–	0.03%	377
2018 Q1	$285K	Buy	3,520 +900	+34%	+$77.2K	0.03%	403
2017 Q4	$234K	Sell	2,620 -700	-21%	-$60.9K	0.02%	436
2017 Q3	$309K	Hold	3,320	–	–	0.03%	416
2017 Q2	$302K	Hold	3,320	–	–	0.03%	423
2017 Q1	$291K	Sell	3,320 -8,700	-72%	-$774K	0.03%	422
2016 Q4	$996	Sell	12,020 -5,400	-31%	-$464K	0.05%	359
2016 Q3	$5.45M	Buy	17,420 +5,400	+45%	+$508K	0.27%	85
2016 Q2	$935K	Hold	12,020	–	–	0.04%	428
2016 Q1	$991K	Hold	12,020	–	–	0.05%	406
2015 Q4	$1.26M	Sell	12,020 -3,700	-24%	-$386K	0.06%	336
2015 Q3	$1.66M	Hold	15,720	–	–	0.09%	267
2015 Q2	$2.15M	Hold	15,720	–	–	0.11%	223
2015 Q1	$1.96M	Sell	15,720 -4,600	-23%	-$487K	0.1%	260
2014 Q4	$1.84M	Hold	20,320	–	–	0.09%	280
2014 Q3	$1.47M	Hold	20,320	–	–	0.06%	394
2014 Q2	$1.26M	Hold	20,320	–	–	0.05%	452
2014 Q1	$1.39M	Buy	+20,320	New	+$1.5M	0.05%	408

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Livforsakringsbolaget Skandia's BMRN Position: Q4 2025 in Review

Livforsakringsbolaget Skandia sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 1,720 shares — an estimated $93.1K sold.

Livforsakringsbolaget Skandia first reported a position in BMRN in Q1 2014 and held it in 47 quarters. The position peaked at $5.45M in Q3 2016. 539 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

Livforsakringsbolaget Skandia reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Livforsakringsbolaget Skandia sold 1,720 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $93.1K.
Livforsakringsbolaget Skandia first reported a position in BioMarin Pharmaceuticals in Q1 2014 and held it in 47 quarters.
Livforsakringsbolaget Skandia's BioMarin Pharmaceuticals position peaked at $5.45M in Q3 2016.
539 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on Livforsakringsbolaget Skandia's 13F filing for Q4 2025, filed 11 Feb 2026.